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Mannose binding lectin (MBL) is a central component of the innate immune response and thus may be
important for determining hepatitis B virus (HBV) persistence. Since single-nucleotide polymorphisms (SNPs)
in the gene encoding MBL (mbl2) alter the level of functional MBL, we hypothesized that mbl2 genotypes are
a determinant of HBV persistence or recovery from viral infection. We tested this hypothesis by using a nested
case control design with 189 persons with HBV persistence matched to 338 individuals who had naturally
recovered from HBV infection. We determined genotypes of two promoter and three exon 1 SNPs in mbl2 and
grouped these genotypes according to the amount of functional MBL production. We found that the promoter
SNP ⴚ221C, which leads to deficient MBL production, was more common in those subjects with viral
persistence (odds ratio [OR], 1.38; 95% confidence interval [CI], 1.01 to 1.89; P ⴝ 0.04). Those subjects
homozygous for the combination of promoter and exon 1 genotypes associated with the highest amount of
functional MBL had significantly increased odds of recovery from infection (OR, 0.55; 95% CI, 0.37 to 0.84; P
ⴝ 0.005). Conversely, those homozygous for the combination of promoter and exon 1 genotypes which produce
the lowest amount of functional MBL were more likely to have viral persistence (OR, 1.76; 95% CI, 1.02 to 3.01;
P ⴝ 0.04). These data are consistent with the hypothesis that functional MBL plays a central role in the
pathogenesis of acute hepatitis B.
the three exon 1 SNPs at codons 52, 54, and 57 by using a
well-characterized cohort of individuals with either HBV persistence or recovery.

Chronic hepatitis B infection affects 400 million people and
is the most common cause of cirrhosis and hepatocellular carcinoma worldwide. Although most adults recover from acute
hepatitis B virus (HBV) infection, it is not fully understood
why some develop chronic hepatitis B. The strength and
breadth of the host immune response are important (3, 30),
and recent data from chimpanzees and transgenic mice suggest
that differences in innate immunity affect recovery from HBV
infection (11, 16).
Mannose binding lectin (MBL) plays a central role in the
innate immune response (32). mbl2, which encodes MBL, is
located on chromosome 10 and consists of four exons (Fig. 1).
Several single-nucleotide polymorphisms (SNPs) in the gene’s
promoter and in exon 1 that ultimately reduce the level of
functional MBL have been described (8). Reduced MBL concentrations have been linked with diminished responses to
several infectious diseases, including human immunodeficiency
virus (HIV) infection and recurrent infections, and higher levels have been linked with inflammatory outcomes such as vascular complications of diabetes mellitus (5, 12, 24, 29). Although one exon 1 SNP has been associated with HBV
persistence (31), this gene and its functionally different haplotypes have not been comprehensively examined in persons
infected with HBV.
We hypothesized that the mbl2 SNPs that reduce functional
MBL levels would be found more often in persons with HBV
persistence and vice versa. To test this hypothesis, we determined genotypes of the promoter SNPs at ⫺550 and ⫺221 and

MATERIALS AND METHODS
Study participants. Subjects in this study were participants in one of two other
studies: (i) the AIDS Link to Intravenous Experience (ALIVE) study, which is an
ongoing study of 2,921 injection drug users enrolled in Baltimore, Md., from
February 1988 to March 1989, as previously described (33), or (ii) the Multicenter AIDS Cohort Study (MACS), which is an ongoing study of 5,622 homosexual men enrolled in one of four U.S. cities between 1984 and 1985 and
between 1987 and 1991 (4, 18).
To investigate the hypothesis that mbl2 SNPs may be associated with recovery
from acute hepatitis B, a nested case control design was used. When possible,
participants from the cohorts with persistent HBV infections were matched to
two persons from the same cohort who had recovered from HBV infection but
who were otherwise similar with regard to nongenetic factors. If two matched
controls were not available, then one control was matched. Matching criteria
included geographic location and factors that have been associated with recovery
from hepatitis B, including age within 10 years, gender, ethnicity, and human
immunodeficiency virus type 1 (HIV-1) infection status (9, 15). Subjects were
considered persistently infected with HBV if their sera or plasma tested positive
for HBV surface antigen (HBsAg) at two visits separated by a minimum of 6
months. Testing for antibodies against HBV core antigen (anti-HBc) and HBsAg
(anti-HBs) was performed as needed to exclude primary HBV infection. Individuals recovered from hepatitis B were positive for anti-HBc and anti-HBs
without the presence of HBsAg at two time points separated by a minimum of 6
months. HBV infection statuses of HIV-positive subjects were determined before antiretroviral therapy was available.
Informed consent was obtained from all participants, and the study was approved by the institutional review boards at all participating institutions.
Serologic testing. All serum specimens were stored at ⫺70°C until testing.
HIV-1 antibody testing was done by enzyme immunoassay, with reactive results
confirmed as positive by Western blotting as previously reported (4, 18, 33).
HBsAg, anti-HBs, and anti-HBc testing was done using commercially available
kits according to the specifications of the manufacturer (AUSZYME, AUSAB,
and CORZYME, respectively; Abbott Laboratories, Abbott Park, IL).
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DNA extraction and mbl2 genotyping. For each individual, cell lines transformed with Epstein-Barr virus were established, and genomic DNA was extracted from these cell lines by using phenol-chloroform.
The mbl2 SNPs at ⫺550, ⫺221, codon 52, and codon 57 were genotyped using
the AcycloPrime-FP SNP detection assay (Perkin Elmer, Boston, MA), a singlebase extension method performed according to the manufacturer’s specifications
(14). In this method, a 200-bp fragment containing the SNP of interest is amplified (primers are listed in Table 1) with cycling conditions of 95°C for 10 min;
35 cycles of 94°C for 15 s, 55°C for 30 s, and 72°C for 60 s; and then a final
extension step of 72°C for 10 min. After amplification, the excess primer and
deoxynucleoside triphosphates are degraded with shrimp alkaline phosphatase
and exonuclease I according to the manufacturer’s specifications. In the final
step, one of two fluorescent terminators representing the alleles present at the
SNP of interest is added to a primer ending immediately upstream of the SNP
site (extension primer). The cycling protocol for the single-base extension step is
95°C for 2 min followed by 15 cycles of 95°C for 15 s and 55°C for 30 s. The results
are identified by the amount of fluorescence polarization (FP) of each allele as
determined by the Victor2V instrument (Perkin Elmer, Boston, MA). We verified the FP results with direct sequencing for 10 samples from each SNP and
found no errors.
The SNP at codon 54 was genotyped by PCR sequence-specific primers with
which two complementary reactions were run for each SNP. The two reactions
shared a common primer, but the second primers differed at their 3⬘-terminal
ends by one base, which represents the bases at the polymorphic alleles. The
PCR products were run on a 1% agarose gel, and an allele was assigned as
present if a band was detected. The procedure was verified by sequencing the

SNPs from 10 individuals with no errors. Ambiguous genotypes from either
method were assigned based on direct sequencing.
Statistical analysis. The first analysis consisted of examining the individual
SNPs. Allele frequencies for each SNP were calculated from the genotypes and
compared with respect to recovery from infection and viral persistence by using
conditional logistic regression (SAS version 10; SAS, Cary, NC). An odds ratio
(OR) of ⬎1 was associated with viral persistence, and an OR of ⬍1 was associated with recovery. Hardy-Weinberg equilibrium was assessed for each SNP by
using the chi-square test with 1 degree of freedom.
Since examining individual SNPs does not fully account for differences in the
amounts of functional MBL produced, we analyzed subjects grouped by genotypes that have been found to correlate with the amount of functional MBL (8).
The group designation system follows previously established nomenclature for
the gene. Groups were established by determining haplotypes consisting of exon
1 and ⫺221 genotypes. Haplotypes were constructed using software designed for
population-based studies, PHASE version 2.0 (http://www.stat.washington.edu
/stephens/software.html) (28). The exon 1 genotype with the C allele at codon 52,
the G allele at codon 54, and the G allele at codon 57 was designated A since this
produces normal levels of functional MBL (Fig. 1 table). If the genotype included one or more of the alternate alleles, T allele at codon 52, A allele at codon
54, or A allele at codon 57, it was designated O since any one of these significantly reduces the amount of functional MBL. The analysis was then expanded
to include the ⫺221 SNP. The genotype with the G allele at ⫺221, which
produces normal levels of functional MBL, was designated Y, whereas that with
the C allele, which profoundly down-regulates the amount of functional MBL,
was designated X. If the exon 1 genotype was O, the ⫺221 SNP was not included
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FIG. 1. Schematic diagram of mbl2 including the gene’s promoter region, which spans 7,100 bases and consists of four exons. An enlarged panel
illustrates the relative positions of the promoter and exon 1 SNPs genotyped in this study. The SNPs in the promoter are designated by a minus
sign and the exon 1 SNPs are designated by their codon numbers, which is the standard nomenclature for this gene. The wild-type and mutant
alleles are designated before and after the SNP numbers, respectively. Below the diagram is a table delineating haplotype names, allele composition
of each haplotype, and frequencies in blacks and whites. The rs numbers for each SNP are indicated in the table and are taken from the Entrez
SNP website (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db⫽Snp). The rs number for the ⫺550 SNP is 11003125.
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TABLE 1. Primers used for FP and sequence-specific
primers (SSP)
Primer namea

Sequence (5⬘ 3 3⬘)

SSP
54B mutant forward ...........CCCCCTTTTCTCCCTTGGTGT
54B wild type forward........CCCCCTTTTCTCCCTTGGTGC
54B reverse..........................CTGCACCCAGATTGTAGGACAGAG
a

Letters in parentheses indicate bases at polymorphic alleles.

since the amount of functional MBL was already so low that it was not significantly altered by the ⫺221 genotype. Thus, the possible haplotypes were YA, XA,
and O. The frequencies of these haplotypes were similar in whites and blacks
(Fig. 1 table), so the analyses were done with the entire cohort and the results
were then stratified by ethnicity if significant. Since each person has two haplotypes, ultimately, six mbl2 genotypes were possible for each subject: YA/YA,
YA/XA, XA/XA, YA/O, XA/O, and O/O. For the analysis, we divided patients into
high-MBL (YA/YA) and low-MBL or MBL-deficient (XA/O and O/O) groups
based on published data regarding MBL concentrations measured in persons
with these genotypes (8). All other genotypes were considered intermediate, and
these groups were compared with respect to recovery from infection and viral
persistence by using conditional logistic regression. The haplotype analyses were
also extended to include the ⫺550 SNP to determine the effect of the ⫺550
promoter SNP.
A P of ⬍0.05 was considered significant in all analyses, and results for any
genotype that met this criterion were stratified by the individuals’ HIV infection
statuses to exclude HIV association. Genotypes were also stratified by subjects’
ethnicity (i.e., black versus white) to evaluate ethnic differences. Since those
subjects in the other-ethnicity category were heterogeneous and small in number,
they were excluded from the ethnicity analysis.

RESULTS
Study subjects. The study group was composed of 189 persons with chronic hepatitis B and 338 persons who had recov-

TABLE 2. Frequencies of mbl2 SNPs and haplotypes in persons
recovered from hepatitis B and those with viral persistence
% Of chromosomesa with the
indicated genotype in:
Genotype

OR

95% CI

P

29.3
23.4
6.6
13.4
5.9

0.82
1.38
0.97
1.35
0.95

0.61–1.09
1.01–1.89
0.58–1.61
0.90–2.03
0.53–1.68

0.17
0.04
0.90
0.15
0.85

51.9
23.0
44.1

0.73
1.40
1.14

0.56–0.94
1.03–1.92
0.78–1.66

0.02
0.03
0.50

Recovered
subjects
(n ⫽ 648–676)

Subjects with
viral persistence
(n ⫽ 372–378)

SNPs
⫺550G
⫺221C (X allele)
Codon 52T
Codon 54A
Codon 57A

33.0
17.7
6.7
10.0
6.8

Haplotypes
YA
XA
O

59.8
17.5
40.9

a

n is the total number of chromosomes for which genotypes were determined
and varies slightly due to the failure of some specimens to amplify for a particular
SNP.

DISCUSSION
In this study, we find that mbl2 genotypes correlating with
high MBL levels are associated with recovery from an HBV
infection whereas those correlating with lower levels are asso-
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FP primers
Exon 1 forward ...................TGGTGGCAGCGTCTTACTCA
Exon 1 reverse ....................CCCAGGCAGTTTCCTCTGGA
52D extension (C/T) ..........CAACGGCTTCCCAGGCAAAGATGGG
57C extension (C/T)...........CAACACGTACCTGGTTCCCCCTTTTCT
⫺550 forward ......................ACTCTGCCAGGGCCAACGTA
⫺550 reverse .......................CAGCTGATTCCCCTCCAGGAC
⫺550 extension (G/C)........GAAAATGCTTACCCAGGCAAGCCTGT
⫺221 forward ......................GGGATTCAGGTGGCAGATGG
⫺221 reverse .......................TGATGAGCAGTGGGGATCCTA
⫺221 extension (G/C)........CGGTCCCATTTGTTCTCACTGCCAC

ered from HBV infection (40 chronically infected persons had
only one match), for a total of 378 and 676 alleles in each
group, respectively. No significant differences were detected
between those recovered from hepatitis B and those with HBV
persistence with respect to the matching criteria: 64% were
HIV positive, the mean age was 34 years, and 98% were male.
The majority of the study group was white (76%), with 22%
black and 2% of other ethnicity.
Individual SNPs and haplotypes. In univariate analysis of
the ⫺550, ⫺221, codon 52, codon 54, and codon 57 SNPs, only
⫺221C (X allele) was associated with viral persistence (OR,
1.38; 95% confidence interval [CI], 1.01 to 1.89; P ⫽ 0.04)
(Table 2). Homozygosity for the X allele was infrequent (3.7%)
and did not strengthen this relationship. Homozygosity for the
Y allele was associated with viral clearance, but the association
was not stronger than that for Y alone (OR, 0.65; P ⫽ 0.03).
None of the other SNPs in either the homozygous or heterozygous state were associated with outcome. The association with
the X allele was the same when results were stratified by black
and white ethnicities and when they were stratified by HIV
infection statuses (Table 4).
Haplotype analysis demonstrated that those with the YA
haplotype were more likely to recover from an HBV infection
(OR, 0.73; 95% CI, 0.56 to 0.94; P ⫽ 0.02). Since the X allele
at ⫺221 occurred only with the A haplotype, the XA haplotype
did not differ from X alone. The O haplotype was not associated with either recovery or viral persistence.
Genotypic groups based on expected functional MBL levels.
Several studies have demonstrated a consistent relationship
between MBL levels and mbl2 genotypes (8, 27). Individuals
homozygous for YA (YA/YA) have the highest levels, whereas
persons with an X allele at ⫺221 on one chromosome and an
O on the other chromosome (XA/O) or who are homozygous
for O (O/O) have the lowest levels (8). Using these previously
established data, we divided our genotypes into one of three
groups: (i) YA/YA, (ii) XA/O or O/O, and (iii) all other combinations, which included those with MBL levels intermediate
between those of the two former groups. Those subjects with the
YA/YA genotype had significantly increased odds of recovery from
infection (OR, 0.55; 95% CI, 0.37 to 0.84; P ⫽ 0.005), whereas
those with XA/O or O/O were more likely to have viral persistence
(OR, 1.76; 95% CI, 1.02 to 3.01; P ⫽ 0.04) (Table 3). A clear
trend between mbl2 genotype and HBV infection outcome was
noted in these three groups (P of 0.002 for Maentel-Haenszel test
for trend). These relationships were not altered with stratification
by HIV infection status or ethnicity (Table 4).
Since a small effect of the ⫺550 promoter on MBL levels has
been demonstrated (8), we divided those with the YA genotype
into two groups based on the ⫺550 SNP. There was no difference in the frequencies of recovery from infection or viral
persistence between those with either C or G at ⫺550 (OR,
0.81 for both groups). Homozygosity for YA with a C at ⫺550
and for YA with a G at ⫺550 also led to similar outcomes (OR,
0.66 and 0.60, respectively).
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TABLE 3. Proportion of individuals with genotypes yielding high, intermediate, and low MBL levels among those recovered from hepatitis B
and those with viral persistence
% Of subjectsb with the indicated MBL
level among:
MBL level (haplotypes)a

95% CI

P

37.9
49.2
13.0

24.6
56.4
19.0

0.55
1.29
1.76

0.37–0.84
0.88–1.87
1.02–3.01

0.005
0.19
0.04

High (YA/YA)
Intermediate (YA/XA, YA/O, or XA/XA)
Low or none (XA/O or O/O)
a
b

The MBL haplotypes are as defined in Materials and Methods.
n, number of study subjects.

ciated with viral persistence. The major role of MBL is activation of complement; however, complement does not play a
known role in HBV pathogenesis. Thus, these data suggest
either a novel mechanism of immune response to HBV involving complement or an alternative role for MBL in HBV pathogenesis.
Although direct binding of MBL to HBV has not been
demonstrated, it could occur since the HBV envelope contains
the required N-acetylglucosamine and mannose recognition
moieties (23). Once bound, the precise role of MBL in clearance of HBV is not known; however, a variety of potential
mechanisms are plausible. A major function of MBL is activation of the classical complement cascade through the cleavage
of C4 and C2 by the MBL-associated serine protease (7). Thus,
whether complement plays a role in HBV pathogenesis deserves investigation. MBL has been associated with antiviral
responses including interference in attachment of influenza A
virus to host cells, viral spread, and viral release (17). In HIV
infection, MBL has been shown to bind to gp120, which prevents binding of the virus to its CD4 receptor (6). It is possible
that such mechanisms may occur with HBV. Another plausible
biological role for MBL is via up- or down-regulation in cytokine production, which occurs in vitro with fungi, parasites, and
bacteria (2, 22, 25). The precise nature of the cytokine response is dependent upon the organism, but alteration of levels
of tumor necrosis factor alpha, which is a cytokine important
for noncytolytic clearance of HBV (10), has been described.
Further work is needed to determine the precise contribution
of MBL to the control of HBV infection.
It is important that the results of genotype and haplotype
analyses were consistent with the relationships found when
individuals were grouped by presumed functional MBL levels.
The ⫺221C (X) allele and the XA haplotype were associated
with viral persistence, and individuals with these genotypes
were found only in groups of subjects producing intermediate
or low levels of MBL. On the other hand, the YA haplotype was

more common in those who recovered from hepatitis B, which
is consistent with the fact that this haplotype was restricted to
the groups with either high or intermediate MBL levels.
It is also notable that the ORs for the significant SNPs and
SNP combinations were similar in both blacks and whites, the
two major ethnic groups in this population. This consistent
trend suggests that MBL is involved directly in HBV clearance
rather than indirectly through linkage disequilibrium with
neighboring loci.
A few other studies have examined mbl2 with respect to
recovery from HBV infection, but the data are inconsistent (1,
13, 26, 31). In the largest of these studies, investigators genotyped the codon 52, 54, and 57 SNPs in 180 Gambians with
persistent HBV infections and 157 who had recovered from
HBV infections (1). The frequency of the codon 57 homozygous mutant was higher in those with viral persistence (8.9%
versus 5.7%) but did not reach statistical significance. The
other SNPs were not present in the homozygous mutant state.
Since the ⫺221 promoter SNP was not examined in this study,
the investigators could not analyze the YA/YA or XA/O genotype. Differences between studies may also be related to the
age of subjects at HBV acquisition. In The Gambia, transmission
of HBV generally occurs in early childhood (34), whereas in the
United States, acquisition is usually in adulthood. Since children
are more likely to have viral persistence after HBV infection (20),
different aspects of the immune system may be relatively more
important depending on whether HBV was acquired before or
during adulthood. Of the other studies, one found an association
between the codon 52 mutation and HBV persistence (31).
It would have been helpful to be able to correlate the precise
levels of MBL in these subjects with the MBL genotypes and
HBV infection outcomes. However, since MBL is an acutephase reactant, the levels in sera when subjects were enrolled
in this study would not be expected to be representative of
levels at the time when HBV persistence or recovery from
infection was determined. In addition, the fact that persons

TABLE 4. ORs for significant SNPs and haplotypes stratified by ethnicity and HIV infection status
Genotype(s)a

⫺221C
YA/YA
XA/O or O/O
a
b

OR (95% CI) for subjects with the following characteristicb:
black (n ⫽ 110)

white (n ⫽ 369)

HIV positive (n ⫽ 330)

HIV negative (n ⫽ 189)

1.53 (0.71–3.30)
0.61 (0.27–1.37)
1.36 (0.42–4.41)

1.41 (0.99–2.00)
0.50 (0.31–0.82)
1.97 (1.06–3.64)

1.34 (0.90–2.01)
0.55 (0.32–0.94)
1.85 (0.86–4.00)

1.55 (0.89–2.69)
0.49 (0.24–1.00)
2.24 (0.93–5.40)

Genotypes are defined in Materials and Methods.
n, number of study subjects with the indicated characteristic.
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Subjects with
viral persistence
(n ⫽ 179)

OR

Recovered subjects
(n ⫽ 301)
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with chronic hepatitis B have an ongoing infection would serve
as a strong confounder in a posthoc evaluation of MBL levels.
A meaningful measurement of MBL levels in our cohort would
require a sample taken prior to HBV infection, which is not
available. Fortunately, there is a well-established relationship
between genotypes and MBL levels, as has been documented
for over 1,000 individuals (8).
Approximately half of our subjects were HIV infected, but
this could not have affected the results of our study for several
reasons. HBV infection occurs prior to HIV infection in most
cases, so the outcome of the viral hepatitis infection is determined prior to acquisition of HIV (19, 21). Even more convincingly, those recovered from infection and those with viral
persistence were matched according to HIV infection status,
and stratification of results of the analysis with respect to HIV
infection status did not significantly alter the results.
In summary, this is the first study to clearly demonstrate that
genetically determined differences in mbl2 are important determinants of recovery from HBV infection. These data support the importance of the innate immune response in this
process, but further study is needed to explain the precise role
of MBL in HBV pathogenesis.

